Literature DB >> 7562593

Chronic antidepressant treatment facilitates G protein activation of adenylyl cyclase without altering G protein content.

J Chen1, M M Rasenick.   

Abstract

It has been suggested that the molecular basis of antidepressant action involves postreceptor components. Results from our studies have suggested that a G protein (Gs) is one of those targets and that chronic antidepressant treatment facilitates the activation of adenylyl cyclase by Gs alpha. This report represents an attempt to define which aspects of G protein function are altered by chronic antidepressant treatment. Rats were treated for 21 days with amitriptyline, desipramine, ABT 200 (a pyrollidine with putative antidepressant effects) or electroconvulsive shock, and membranes were prepared from the cerebral cortexes. Each of these treatments caused an increase in membrane adenylyl cyclase assayed in the presence of guanyl-5'-imidodiphosphate (> or = 1 microM). Results of acute antidepressant treatments were no different than those of control treatment. Chronic treatment with amphetamine, which inhibits neurotransmitter reuptake without displaying antidepressant effect, was also ineffective in increasing Gs alpha stimulation of adenylyl cyclase. Chronic antidepressant treatment did not change the content of G protein, as no change at the level of Gs alpha, Gi alpha, Go alpha or G beta protein was detected by immunoblotting. Although there was no change in the amount of G proteins, antidepressant treatment increased the number of active Gs alpha/adenylyl cyclase complexes immunoprecipitated by an anti-Gs alpha antibody. It is suggested that chronic antidepressant treatment alters certain membrane components such that a greater proportion of Gs alpha is activated, Gs alpha enjoys a more fruitful interaction with adenylyl cyclase, or both.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7562593

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  10 in total

1.  Chronic treatment with escitalopram but not R-citalopram translocates Galpha(s) from lipid raft domains and potentiates adenylyl cyclase: a 5-hydroxytryptamine transporter-independent action of this antidepressant compound.

Authors:  Lanqiu Zhang; Mark M Rasenick
Journal:  J Pharmacol Exp Ther       Date:  2009-12-08       Impact factor: 4.030

Review 2.  The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders.

Authors:  G MacQueen; L Born; M Steiner
Journal:  CNS Drug Rev       Date:  2001

3.  Alterations of tubulin function caused by chronic antidepressant treatment in rat brain.

Authors:  H Kamada; T Saito; S Hatta; S Toki; H Ozawa; M Watanabe; N Takahata
Journal:  Cell Mol Neurobiol       Date:  1999-02       Impact factor: 5.046

4.  Selective activation of Galphao by D2L dopamine receptors in NS20Y neuroblastoma cells.

Authors:  V J Watts; B L Wiens; M G Cumbay; M N Vu; R L Neve; K A Neve
Journal:  J Neurosci       Date:  1998-11-01       Impact factor: 6.167

5.  Lateral diffusion of Gαs in the plasma membrane is decreased after chronic but not acute antidepressant treatment: role of lipid raft and non-raft membrane microdomains.

Authors:  Andrew H Czysz; Jeffrey M Schappi; Mark M Rasenick
Journal:  Neuropsychopharmacology       Date:  2014-09-24       Impact factor: 7.853

6.  Antidepressants, but not antipsychotics, modulate GR function in human whole blood: an insight into molecular mechanisms.

Authors:  L A Carvalho; B A Garner; T Dew; H Fazakerley; C M Pariante
Journal:  Eur Neuropsychopharmacol       Date:  2010-03-15       Impact factor: 4.600

7.  Diverse antidepressants increase CDP-diacylglycerol production and phosphatidylinositide resynthesis in depression-relevant regions of the rat brain.

Authors:  Kimberly R Tyeryar; Habiba O U Vongtau; Ashiwel S Undieh
Journal:  BMC Neurosci       Date:  2008-01-24       Impact factor: 3.288

Review 8.  The Role of G-proteins and G-protein Regulating Proteins in Depressive Disorders.

Authors:  Nicolas B Senese; Mark M Rasenick; John R Traynor
Journal:  Front Pharmacol       Date:  2018-11-13       Impact factor: 5.810

9.  Can targeted metabolomics predict depression recovery? Results from the CO-MED trial.

Authors:  Andrew H Czysz; Charles South; Bharathi S Gadad; Erland Arning; Abigail Soyombo; Teodoro Bottiglieri; Madhukar H Trivedi
Journal:  Transl Psychiatry       Date:  2019-01-16       Impact factor: 6.222

Review 10.  Novel Molecular Targets of Antidepressants.

Authors:  Małgorzata Jarończyk; Jarosław Walory
Journal:  Molecules       Date:  2022-01-14       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.